HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .
Low-dose tibolone (1.25 mg/d) does not affect muscle strength in older women
Objective : More than 50 % of all fractures occur in people without osteoporosis . Hormone therapy increases bone density , improves postural balance , and reduces fracture risk in postmenopausal women . It is unclear whether tibolone , a synthetic steroid hormone drug , can improve muscle strength . Thus , the aim of this study was to study the effects of low-dose tibolone therapy on muscle strength in older women . Methods : Eighty healthy women ( 69 completed the study ) 60 years or older were recruited through advertising in the local media . They were r and omly allocated to receive either tibolone 1.25 mg/day or placebo for 6 months . The st and -up test was used to assess leg muscle strength and balance . H and grip and leg muscle strength were measured using JAMAR and modified Cybex dynamometers . Results : Baseline characteristics , including serum estradiol values and muscle strength , were similar in the two groups .  Compliance with the therapy regimen was very high , averaging more than 97 % in both groups . After 6 months , mean values for h and grip strength , knee extensor strength , and average time to perform 10 st and s were improved numerically in both groups compared with values during baseline . However , there were no significant differences in these parameters within or between groups , and differences remained nonsignificant after adjustment for age , serum estradiol , and baseline value . Conclusions : Short-term treatment with low-dose tibolone ( 1.25 mg/d ) seems not to affect muscle strength in older women
HT treatment with estrogens alone or in combination with progestogens was associated with a small to moderate improvement in sexual function , particularly in pain , when used in women with menopausal symptoms or in early postmenopause ( within five years of amenorrhoea ) , but not in unselected postmenopausal women .
The current evidence does not suggest an important effect of tibolone or of SERMs alone or combined with estrogens on sexual function .
BACKGROUND The perimenopausal and postmenopausal periods are associated with many symptoms , including sexual complaints .
OBJECTIVES To assess the effect of hormone therapy ( HT ) on  sexual function in perimenopausal and postmenopausal women .